{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-25-045836","form_type":"8-K","ticker":"INSM","cik":"0001104506","company_name":"INSMED Inc","filed_at":"2025-12-17T23:59:59+00:00","discovered_at":"2026-05-14T18:02:38.803600+00:00","generated_at":"2026-05-16T12:51:55.959730+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Insmed brensocatib fails Phase 2b CRSsNP; acquires INS1148 antibody","bullets":["Phase 2b BiRCh study missed primary endpoint: placebo LS mean -2.44, brensocatib 10mg -2.21, 40mg -2.33.","All secondary endpoints also not met; Insmed discontinues CRSsNP program immediately.","Brensocatib well tolerated with no new safety signals; 40 mg dose had 69.9% TEAEs vs 65.3% placebo.","Acquired INS1148 (anti-SCF248 mAb) from Opsidio; plans Phase 2 in interstitial lung disease and asthma.","INS1148 targets only inflammatory c-Kit signaling, sparing homeostatic pathways, potentially first-in-class."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-25-045836","json":"https://secwatch.observer/filing/0001140361-25-045836.json","markdown":"https://secwatch.observer/filing/0001140361-25-045836.md","text":"https://secwatch.observer/filing/0001140361-25-045836.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1104506/000114036125045836/0001140361-25-045836-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1104506/000114036125045836/ef20061465_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T12:51:55.959730+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}